The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer—A Phase II Study

Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single Arm Phase II Feasibility Trial (PERFECT)

(2021) Tom van den Ende et al.   CLINICAL CANCER RESEARCH

Paradigms on Immunotherapy Combinations with Chemotherapy

(2021) Diego Salas-Benito et al.   Cancer Discovery

Impact of the combined timing of PD-1/PD-L1 inhibitors and chemotherapy on the outcomes in patients with refractory lung cancer

(2021) W. Yao et al.   ESMO Open

Neoadjuvant checkpoint blockade for cancer immunotherapy

(2020) Suzanne L. Topalian et al.   SCIENCE

Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study

(2020) Jing Huang et al.   LANCET ONCOLOGY

LBA8_PR Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study

(2020) K. Kato et al.   ANNALS OF ONCOLOGY

Updates in staging and pathologic evaluation of esophageal carcinoma following neoadjuvant therapy

(2020) Xuchen Zhang et al.   ANNALS OF THE NEW YORK ACADEMY OF SCIENCES

Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer

(2020) Aranzazu Fernandez-Martinez et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer

(2020) Kohei Shitara et al.   JAMA Oncology

Progress in Multimodal Treatment for Advanced Esophageal Squamous Cell Carcinoma: Results of Multi-Institutional Trials Conducted in Japan

(2020) Kazuo Koyanagi et al.   Cancers

Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)

(2020) Chengqiang Li et al.   EUROPEAN JOURNAL OF CANCER

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer – clinical results and biomarker analysis of GeparNuevo study

(2019) S Loibl et al.   ANNALS OF ONCOLOGY

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

(2019) Leonie Voorwerk et al.   NATURE MEDICINE

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

(2019) Ken Kato et al.   LANCET ONCOLOGY

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

(2018) Patrick M. Forde et al.   NEW ENGLAND JOURNAL OF MEDICINE

The MR radiomic signature can predict preoperative lymph node metastasis in patients with esophageal cancer

(2018) Jinrong Qu et al.   EUROPEAN RADIOLOGY

Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial

(2018) Hong Yang et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

(2018) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer of the Esophagus and Esophagogastric Junction: An Eighth Edition Staging Primer

(2017) Thomas W. Rice et al.   Journal of Thoracic Oncology

Cancer statistics in China, 2015

(2016) Wanqing Chen et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery

(2016) Jack M. Qian et al.   CANCER

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide

(2016) Genevieve M. Weir et al.   Journal for ImmunoTherapy of Cancer

Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial

(2015) Joel Shapiro et al.   LANCET ONCOLOGY

Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer

(2012) P. van Hagen et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907)

(2011) Nobutoshi Ando et al.   ANNALS OF SURGICAL ONCOLOGY

Influence of preoperative chemotherapy for advanced thoracic oesophageal squamous cell carcinoma on perioperative complications

(2011) M. Hirao et al.   BRITISH JOURNAL OF SURGERY